# Forty Seven

Source: https://onco.cc/companies/forty-seven/  
OnCo record `forty-seven` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Forty Seven developed magrolimab, an antibody that blocks CD47, a signal cancer cells use to stop immune cells from swallowing them. Gilead bought the company in 2020.

## Summary

Forty Seven, Inc. (formerly Nasdaq: FTSV), of Menlo Park, California, was a clinical-stage immuno-oncology company working on technology licensed from Stanford University. Its lead programme, magrolimab, is a monoclonal antibody against CD47, a 'don't eat me' signal that cancer cells use to avoid being engulfed by macrophages; at the time of sale it was in clinical studies in myelodysplastic syndrome, acute myeloid leukaemia and diffuse large B-cell lymphoma. Gilead agreed on 2 March 2020 to buy Forty Seven for USD 95.50 per share in cash, valuing it at about USD 4.9 billion, and the merger was completed on 7 April 2020.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: Forty Seven, Inc.; NASDAQ:FTSV
- HQ: Menlo Park, CA
- Type: biotech

## Notes

- Completion on 7 April 2020 is from Forty Seven's 8-K of that date. What later happened to magrolimab is on its own page; this record does not restate it. No website or founding year is recorded.

## Sources

- Gilead to acquire Forty Seven (8-K exhibit 99.1, 2 March 2020): https://www.sec.gov/Archives/edgar/data/1667633/000119312520057799/d890968dex991.htm
- Form 8-K: completion of the merger (7 April 2020): https://www.sec.gov/Archives/edgar/data/1667633/000110465920043980/a20-14980_68k.htm

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD47](https://onco.cc/targets/cd47/)
- drugs: [Magrolimab](https://onco.cc/drugs/magrolimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/forty-seven.json